Cargando…

Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens

BACKGROUND: The highly attenuated vaccinia virus strain NYVAC expressing HIV-1 components has been evaluated as a vaccine candidate in preclinical and clinical trials with encouraging results. We have previously described that the presence of C7L in the NYVAC genome prevents the induction of apoptos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nájera, José Luis, Gómez, Carmen Elena, García-Arriaza, Juan, Sorzano, Carlos Oscar, Esteban, Mariano
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2894869/ https://www.ncbi.nlm.nih.gov/pubmed/20613977 http://dx.doi.org/10.1371/journal.pone.0011406

Ejemplares similares

P17-07. Insertion of a vaccinia virus host range (hr) gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens
por: Najera, JL, et al.
Publicado: (2009)

Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways
por: Gómez, Carmen Elena, et al.
Publicado: (2017)

Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C
por: Perdiguero, Beatriz, et al.
Publicado: (2013)

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions
por: García-Arriaza, Juan, et al.
Publicado: (2010)

A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses
por: García-Arriaza, Juan, et al.
Publicado: (2011)

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways
por: García-Arriaza, Juan, et al.
Publicado: (2013)

Correction for Kibler et al., “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC”
por: Kibler, Karen V., et al.
Publicado: (2019)

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
por: Pérez, Patricia, et al.
Publicado: (2020)

Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression
por: Q. Marín, María, et al.
Publicado: (2018)

An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design
por: Pérez, Patricia, et al.
Publicado: (2019)

Improved NYVAC-Based Vaccine Vectors
por: Kibler, Karen V., et al.
Publicado: (2011)

A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen
por: Vijayan, Aneesh, et al.
Publicado: (2015)

Involvement of the Cellular Phosphatase DUSP1 in Vaccinia Virus Infection
por: Cáceres, Ana, et al.
Publicado: (2013)

Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors
por: Quakkelaar, Esther D., et al.
Publicado: (2011)

Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens
por: Perdiguero, Beatriz, et al.
Publicado: (2012)

Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax
por: Midgley, Claire M., et al.
Publicado: (2008)

A Human Multi-Epitope Recombinant Vaccinia Virus as a Universal T Cell Vaccine Candidate against Influenza Virus
por: Goodman, Alan G., et al.
Publicado: (2011)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
por: García-Arriaza, Juan, et al.
Publicado: (2021)

COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice
por: García-Arriaza, Juan, et al.
Publicado: (2021)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012)

Neutrophil subtypes shape HIV-specific CD8 T-cell responses after vaccinia virus infection
por: Di Pilato, Mauro, et al.
Publicado: (2021)

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
por: Harari, Alexandre, et al.
Publicado: (2008)

Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 Protein Antigen
por: Knudsen, Maria L., et al.
Publicado: (2015)

Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study
por: Perdiguero, Beatriz, et al.
Publicado: (2022)

A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice
por: Pérez, Patricia, et al.
Publicado: (2018)

Induction of Broad and Polyfunctional HIV-1-Specific T Cell Responses by the Multiepitopic Protein TMEP-B Vectored by MVA Virus
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
por: Perdiguero, Beatriz, et al.
Publicado: (2018)

Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen
por: Gómez, Carmen Elena, et al.
Publicado: (2021)

OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
por: Jacobs, B, et al.
Publicado: (2009)

Host-Range Restriction of Vaccinia Virus E3L Deletion Mutant Can Be Overcome In Vitro, but Not In Vivo, by Expression of the Influenza Virus NS1 Protein
por: Guerra, Susana, et al.
Publicado: (2011)

Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV
por: Marín, María Q., et al.
Publicado: (2020)

An Update on the Known Host Range of the Brazilian Vaccinia Virus: An Outbreak in Buffalo Calves
por: Lima, Mauricio Teixeira, et al.
Publicado: (2019)

The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1
por: Raman, Suresh C., et al.
Publicado: (2019)

High Quality Long-Term CD4(+) and CD8(+) Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in Leishmania major BALB/c Model of Infection
por: Sánchez-Sampedro, Lucas, et al.
Publicado: (2012)

rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
por: Bart, P, et al.
Publicado: (2012)

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART
por: Gómez, Carmen Elena, et al.
Publicado: (2015)

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
por: Pantaleo, Giuseppe, et al.
Publicado: (2019)

Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a Vaccinia virus recombinant
por: Gómez, Carmen E, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_5jlpibrbnvn0s51dimk765bvgm